79Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Portugal
Neuroscience Intelligence
Portugal neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #24 of 50 · Data maturity A · Research score 36.0 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
27Recruiting trials
51Publications
73Institutions
Executive interpretation
Portugal ranks #24 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Hoffmann-La Roche93 recruiting
Bial - Portela C S.A.90 recruiting
AbbVie31 recruiting
University of Coimbra32 recruiting
Novo Nordisk A/S30 recruiting
Merck Sharp & Dohme LLC33 recruiting
Bayer22 recruiting
GlaxoSmithKline20 recruiting
Boehringer Ingelheim20 recruiting
Celgene20 recruiting
Disease activity
Alzheimers15trials
Parkinsons13trials
Epilepsy11trials
Multiple Sclerosis7trials
Stroke3trials
Schizophrenia3trials
Autism3trials
Migraine Headache3trials
Other Psychiatry2trials
Huntingtons2trials
Research institutions
Hospital de São JoséOpenAlexlinked institution
Sociedade Portuguesa de CardiologiaOpenAlexlinked institution
Instituto de Ciências Biomédicas Albel SalazarOpenAlexlinked institution
Centro de Investigação Interdisciplinar Egas MonizOpenAlexlinked institution
University of Trás-os-Montes and Alto DouroOpenAlexlinked institution
Centro de Investigação e de Tecnologias Agro-Ambientais e BiologicasOpenAlexlinked institution
Centro Hospitalar de Vila Nova de GaiaOpenAlexlinked institution
Escola Superior de Enfermagem de CoimbraOpenAlexlinked institution
Hospital da Senhora da Oliveira GuimarãesOpenAlexlinked institution
Unidade Local de Saúde de São JoséOpenAlexlinked institution
Clinical evidence trail
NCT07754929E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer SurvivorsRECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineACTIVE_NOT_RECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDLocus Coeruleus mediates the pharmacological effects of 2-Pentadecyl-2-oxazoline in a mouse model of neuropathic pain.2026-12-15
PUBMEDDysfunctional Brain Circuits Overlap in Lesional and Idiopathic Obsessive-Compulsive Disorder.2026-11-01
PUBMEDBeyond WEIRD populations: Interpreting the gap between subjective cognitive complaints and objective impairment.2026-10-09
PUBMEDAssessing neuropsychiatric symptoms in context: Integrating standardized and ecological approaches for better care.2026-10-08
PUBMEDIrritable versus euphoric mania in psychiatric inpatients: a retrospective study of 251 inpatient episodes.2026-10-05
PUBMEDRelieving pain with OnabotulinumtoxinA in refractory burning mouth syndrome: protocol and outcomes of an exploratory case series.2026-10-02
PUBMEDPseudotumoral multiple sclerosis: unveiling its clinical and imaging characteristics.2026-10-01
PUBMEDEnhanced spinal motoneuron excitability as a marker of motor neuron dysfunction in primary lateral sclerosis.2026-10-01
PUBMEDAn integrated framework for clinical surveillance in multiple sclerosis: An evidence-informed narrative review.2026-09-24
PUBMEDTryptophan-enriched diet improves social behavior in a mouse model of tuberous sclerosis complex.2026-09-18
PUBMEDPhrenic nerve amplitude as an effort-independent prognostic biomarker of respiratory failure in amyotrophic lateral sclerosis.2026-09-08
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.